{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "TWST", "name": "Twist Bioscience Corporation", "url": "https://orbyd.app/dossiers/TWST/", "json_url": "https://orbyd.app/dossiers/TWST.json", "status": "DORMANT", "current_conviction": "MEDIUM", "graded_conviction": "LOW", "archetype": { "code": "a3", "n": 3 }, "current_thesis": "Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and Evercore stepped aside on valuation. The 2026-08-03 Q3 print is the binary that decides whether AI orders show up in the total revenue line.", "invalidation_trigger": "A weekly close below $80 — the old all-time-high ceiling that became support on the late-June breakout — voids the AI-order re-rating leg. Secondary: the 2026-08-03 Q3 FY26 print showing total revenue growth still stuck near +19% with no inflection from AI accounts.", "catalyst_date": null, "outcome": "PLAYED_OUT", "outcome_date": "2026-06-11", "invalidation_fired": false, "themes": [ "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "CORRECTION vs the last refresh: the $70-pivot breakout did NOT stay failed. The 2026-06-05 close at $69.22 was the low of the pullback; price reclaimed $70, cleared the $80.50 old ATH in late June, and printed $105.47 in early July. The 'momentum broken' read was wrong and has been retired.", "Price ($93.85, 2026-07-17) trades ABOVE the 11-analyst average PT of $85.50 even after the July raises — the average is dragged by stale sub-$70 targets. The live cluster is $102 (Evercore), $107 (Guggenheim), $110 (Leerink), $120 (Canaccord).", "Evercore ISI's 2026-07-06 downgrade to In Line is the single most useful bear datapoint: PT RAISED $66 -> $102 while the rating was cut. Analyst Vijar Kumar's exact objection — 'while AI revenues have doubled, the overall revenue trends for the company have been consistent and have not inflected' — is the thing 2026-08-03 either resolves or confirms.", "Still GAAP-unprofitable: TTM net loss -$81.28M on TTM revenue $409.48M. FY25 loss -$77.67M (improved from -$121.8M). Adj-EBITDA breakeven is targeted for Q4 FY26 — that is not GAAP profit and the cash-burn/dilution lever stays live.", "Mixed-shelf prospectus filed 2026-06-18, terms undisclosed, and no takedown has priced as of 2026-07-19. A raise into a $5.8B cap after a 200% run is the most likely near-term supply event; assume it is coming, not that it was abandoned.", "CEO Emily Leproust sold ~$3.2M of stock on 2026-05-26/27 (Form 4), days after the analyst day. Watch for follow-on Form 4s in the $90-105 zone — clustered insider distribution at the highs would be the earliest saturation signal.", "Beta 2.11 on a 62.27M share float. Position sizing must assume 10-15% single-day gaps in both directions; this behaves like a high-beta momentum vehicle, never a core holding.", "Investor Day 2026-05-21 set the long frame: ~$1B revenue by FY2031 (>16% CAGR), adj-EBITDA breakeven Q4 FY26, sustained adj-EBITDA profitability FY27, plus the Complex Genes early-access launch aimed at AI-drug-discovery and nucleic-acid-therapeutics accounts. 85% of the YTD move dates from this event." ], "body_markdown": "## Current Thesis\nTwist manufactures synthetic genes, oligo pools and DNA libraries — the physical consumables that AI protein-design and antibody-discovery pipelines convert compute into wet-lab results with. For most of the last two years that was a steady tools business compounding ~20% with a widening loss. Since the 2026-05-21 Investor Day it has been repriced as an AI-demand story, and the repricing was violent: the stock is up more than 200% YTD with roughly 85% of the move coming after that single event, per Evercore ISI's 2026-07-06 note.\n\nThe structural read from the prior refresh has to be retired. The early-June breakout looked failed — a +10% gap to $80.50 on 2026-06-04 reversed 6.37% to close $69.22 on 2026-06-05, back under the $70 pivot. That was the low. Price reclaimed $70 through late June on a dense analyst cluster, cleared the old $80.50 ceiling, and tagged $105.47 in the first week of July. It has since consolidated to $93.85 (2026-07-17), about 11% under the high.\n\nWhat an investor is buying at this level is the second derivative: not that Twist grows 19%, but that AI-drug-discovery accounts inflect the total revenue line above that. Evercore's downgrade names exactly the gap — AI revenues doubled while consolidated growth stayed flat. The 2026-08-03 Q3 FY26 print is where that gets settled.\n\n## Bull Case\n- **Target cluster re-rated three times in six weeks, each above the last ceiling.** Piper Sandler initiated Overweight $85 (2026-06-11), Canaccord initiated Buy $90 (2026-06-15), TD Cowen $89 (2026-06-15), Barclays $95 (2026-06-24), Guggenheim $107 (2026-06-29), Leerink $80 → $110, Canaccord again $90 → $120 (2026-07-09). Sequential raises from firms that already owned the name is what narrative acceleration looks like on the sell side.\n- **Record Q2 FY26 on 2026-05-04: revenue $110.7M, +19.3% YoY, gross margin 51.6%** — the 13th consecutive quarter of sequential revenue growth. TTM revenue now $409.48M, +17.8%.\n- **FY26 guide raised to $442–447M; Q3 FY26 guided $114–115M** on the same print.\n- **Investor Day 2026-05-21 reset the terminal frame:** ~$1B revenue by FY2031 (>16% CAGR), adj-EBITDA breakeven targeted Q4 FY26, sustained adj-EBITDA profitability by FY27, plus a Complex Genes early-access launch pointed directly at AI-drug-discovery and nucleic-acid-therapeutics buyers.\n- **Loss line is compressing.** FY25 net loss -$77.67M against -$121.8M the prior year, on 20.3% revenue growth. Operating leverage is arriving before the AI mix shift, which means an AI-order inflection lands on an already-improving cost base.\n- **The move has held its gains.** A 200%+ YTD advance that pulls back only 11% from the high and consolidates above $90 is distribution-resistant; a broken parabola gives back a third.\n\n## Bear Case\n- **Evercore ISI cut to In Line on 2026-07-06 while raising the target $66 → $102.** Analyst Vijar Kumar: \"while AI revenues have doubled, the overall revenue trends for the company have been consistent and have not inflected.\" A doubling off a small base inside a business still growing 19% is a mix story dressed as an inflection. This is the sharpest objection on the tape and it is unresolved until 2026-08-03.\n- **Price trades above consensus.** $93.85 against an 11-analyst average PT of $85.50. The average is dragged by stale sub-$70 targets, but it means the marginal buyer is paying above where the median covering analyst thinks fair value sits.\n- **Mixed-shelf prospectus filed 2026-06-18, terms undisclosed, still unpriced.** A company burning cash toward a Q4 FY26 adj-EBITDA breakeven, sitting at a $5.84B market cap after a 200% run, has every incentive to take that shelf down. Assume supply is coming.\n- **CEO Emily Leproust sold ~$3.2M (Form 4, 2026-05-26/27)**, days after the Investor Day that started the move.\n- **Still GAAP-unprofitable:** TTM net loss -$81.28M. \"Adj-EBITDA breakeven\" excludes stock comp, which on a 62.27M-share float is the dilution mechanism itself.\n- **Beta 2.11.** The name amplifies any XBI or small-cap risk-off move and gaps double digits on sentiment alone.\n\n## Setup & Price Structure\nThe relevant shelf is no longer $70 — that level is 25% below spot and irrelevant. The structure now: a late-June breakout through the $80.50 prior all-time high, a run to $105.47 in the first days of July, and a two-week consolidation that has held the $90 handle. $80 is the line that matters underneath, the old ceiling that has to behave as support for the July leg to stay intact.\n\nOverhead, $105.47 is the level a continuation has to clear, and the $110–120 targets from Leerink and Canaccord are the first Street marks that sit above it — the same setup that existed in late June when the $85–95 cluster preceded the break of $80.\n\nThe awkward part of the tape is timing. This is a consolidation above a breakout, which is normally where a continuation entry belongs, but the Q3 print lands 2026-08-03 with the stock carrying a 200% YTD move and one covering analyst already on the sidelines. Entering inside three trading days of that print is a coin flip on a 2.11-beta name, not a momentum trade. The cleaner sequence is either a position established well ahead of the blackout window with sizing that survives a 15% gap, or waiting for the print and buying the reaction if AI orders show up in the consolidated number.\n\nWhere this sits in the trap matrix: retail sentiment is warm but not peak — the coverage is sell-side, not Reddit. Price is roughly 11% off its high rather than stretched far above the moving averages, so mean-reversion risk from extension alone is moderate. The genuine hazards are the unpriced shelf and the earnings date.\n\n## Catalyst Calendar (next 30 days)\n\n- **Rolling:** Form 4 filings. Follow-on insider sales in the $90–105 zone after the May distribution would be the earliest saturation signal.\n- **Rolling:** further target revisions. The unrevised firms still carry sub-$90 marks; raises from those laggards extend the cluster, while a second rating downgrade on valuation grounds after Evercore's would mark the sell-side leg as spent.\n\n## Elapsed catalysts\n\n- **2026-08-03 (confirmed):** Q3 FY26 results before the open, ended 2026-06-30; conference call 08:00 ET. The binary. Watch three things — whether consolidated revenue beats the $114–115M guide, whether management quantifies AI-account revenue as a percentage of the total, and whether the Q4 adj-EBITDA breakeven commitment is reaffirmed. *(passed 6d ago)*\n- **Any date, pending:** takedown pricing off the 2026-06-18 mixed shelf. Unpriced as of 2026-07-19. A large discounted raise caps the move regardless of the new targets; a small or absent one removes the overhang. *(passed 21d ago)*\n\n## What Would Change Our Mind\n- **A weekly close below $80** surrenders the old all-time-high ceiling that the late-June breakout converted to support and puts price back inside the June base — the AI-order re-rating leg is finished at that point.\n- **A 2026-08-03 print showing total revenue growth still near +19% with no disclosed AI-mix inflection** validates Evercore's objection and reduces this to a 20%-grower trading at ~14x TTM revenue.\n- **A shelf takedown priced at a meaningful discount to spot**, or upsized beyond housekeeping scale, changes the supply picture for months.\n- **Clustered follow-on insider sales above $95.**\n- Conversely, a **beat-and-raise on 2026-08-03 with AI accounts broken out and quantified** — plus targets migrating toward the $110–120 band across the coverage group rather than at two firms — takes conviction up and makes $105.47 a base rather than a top.\n\n## Correlation Notes\n- Trades with life-science tools and the AI-drug-discovery complex rather than with therapeutic biotech: read ILMN, PACB, and CRSP alongside it, plus RXRX and SDGR on the AI-discovery side. Cluster confirmation in this group is what separates a Twist-specific narrative from a sector-wide multiple expansion.\n- High sensitivity to XBI and small-cap risk appetite via the 2.11 beta. Rate-driven risk-off compresses unprofitable growth names in this cohort first.\n- Second-order exposure to AI-lab capex. Demand comes from pharma and AI-native drug-discovery firms funding wet-lab validation, so it correlates with private AI-biotech funding announcements more than with hyperscaler capex.\n- Also carries an optical link to DNA data storage through Atlas Data Storage, the technology spin-out. Atlas headlines can move sentiment without touching Twist's consolidated revenue — treat those moves as noise unless a commercial agreement is disclosed.", "first_seen": "2026-04-22", "last_analyzed": "2026-08-07T06:10:36+00:00", "last_synthesized": "2026-07-19", "last_update_source": "theme_discovery", "license": "Content © orbyd. Cite the canonical URL." }